Toggle navigation
Goals &
Objectives
Distinguished
Faculty
Education &
Resources
Contact
Us
Toggle navigation
Goals & Objectives
Distinguished Faculty
Education & Resources▼
CME Programs
Find a Clinician
SpeakerReady
Polling Questions
Conference Calendar
Refer a Colleague
Literature
Resources
Contact
Polling Questions
According to Dr Harsh, which of the following is true of bremelanotide?
a. FDA approved in June 2019
b. Treats generalized, acquired hypoactive sexual desire disorder in premenopausal women
c. Subcutaneous use 45 minutes before sexual activity
d. All of the above
Your answers are confidential and will be used for educational purposes only.
Submit